Hepatitis and Liver Cirrhosis

From a Western standpoint, hepatitis and cirrhosis represent stages along a modifiable disease spectrum. Persistent inflammatory injury from HBV, HCV, alcohol, or metabolic dysfunction drives fibrosis via stellate cell activation and extracellular matrix deposition. Over time, this culminates in cirrhosis with portal hypertension and oncogenic risk. The transformative insight of the last decade is that etiology-targeted therapy changes long-term outcomes: tenofovir/entecavir for HBV and pan-genotypic DAAs for HCV lower the incidence of cirrhosis, decompensation, and HCC, with evidence of fibrosis regression—especially when started before advanced architectural distortion. In parallel, addressing accelerants is essential: structured alcohol cessation, diabetes control, and weight loss have tangible antifibrotic benefits in earlier disease. Modern practice emphasizes early identification using noninvasive fibrosis tools (transient elastography, FIB-4), guideline-based antiviral initiation, vaccination (HBV, HAV), and harm reduction. Once cirrhosis exists, the focus broadens to preventing and managing complications—nonselective beta-blockers for portal hypertension where indicated, endoscopic variceal ligation when needed, diuretic-based ascites control, hepatic encephalopathy management, and HCC surveillance every six months. Even after HCV cure or HBV suppression, patients with advanced fibrosis require ongoing surveillance and cardiometabolic risk modification. For selected patients with decompensation or HCC within criteria, liver transplantation remains definitive therapy. The actionable message: test early, treat the cause, remove accelerants, and institute cirrhosis-specific prophylaxis and surveillance.

Eastern traditions view chronic hepatitis and cirrhosis as manifestations of disrupted internal balance—stagnant qi and blood, damp-heat, and depletion of foundational energies that impair the Liver’s transformative functions. Treatment aims to clear heat and dampness, move blood, soothe Liver qi, and strengthen spleen/kidney, thereby reducing symptoms such as fatigue, poor appetite, pruritus, and mood disturbance. In practice, individualized herbal formulas (e.g., damp-heat–clearing or blood-moving prescriptions) and acupuncture are combined with diet and lifestyle that reduce internal heat and stagnation. Ayurveda likewise seeks to pacify pitta, improve agni (digestive fire), and reduce ama with herbs (e.g., Phyllanthus species), gentle yoga, and breathwork to moderate stress—a known amplifier of symptom burden. As adjuncts to biomedical care, these approaches can support quality of life and self-management (sleep, appetite, energy, stress). Safety and integration are paramount: some botanicals are hepatotoxic or interact with antivirals and beta-blockers, and dosing must consider impaired metabolism in cirrhosis. Collaboration with licensed practitioners and disclosure to the hepatology team help ensure compatibility with antiviral therapy, portal hypertension prophylaxis, and diuretics. Framed this way, Eastern modalities complement the Western imperative to control etiology and prevent complications—offering symptom relief and lifestyle scaffolding while evidence for disease-modifying effects continues to evolve.